Does artificial nutrition improve outcome of critical illness? An alternative viewpoint!

Recent studies challenge the beneficial role of artificial nutrition provided to critically ill patients and point out the limitations of existing studies in this area. We take a differing view of the existing data and refute many of the arguments put forward by previous authors. We review the mechanistic, observational, and experimental data supporting a role for early enteral nutrition in the critically ill patient. We conclude without question that more, high-quality research is needed to better define the role of artificial nutrition in the critical care setting, but until then early and adequate delivery of enteral nutrition is a legitimate, evidence-based treatment recommendation and we see no evidence-based role for restricting enteral nutrition in critically ill patients. The role of early supplemental parenteral nutrition continues to be defined as new data emerge.

When artifi cial nutrition was fi rst introduced decades ago, it was considered metabolic supportive care for the critically ill, catabolic patient unable to ingest alimen tation by mouth. As such, initial evaluation studies were small, single-centered, and focused on nutritional or metabolic outcome parameters. We acknowledge our original studies were weak, but we have come a long way since those days. Now our sample sizes are much larger, studies are more likely to be multicentered, trials are now focused only on critically ill patients (and not elective surgery), and trials are powered for clinically important primary outcomes such as mortality and infection [1]. We agree with Dr Schetz and colleagues that we desperately need more high-quality research in the ICU nutrition fi eld, but we disagree with their interpretation of the existing evidence about the impact of nutrition in the critically ill patient [2]. In particular, we suggest that the unphysiologic intervention of artifi cial nutrition applies mostly to parenteral nutrition (PN), particularly high-dose intravenous glucose administration, not to stan dard enteral nutrition (EN). We do not consider that EN and PN should be considered as equal therapies and their safety and effi cacy warrant separate comments.
One derives the truth about the merits of a particular intervention after careful, explicit, and conscientious consideration of all the evidence related to the particular intervention. Th is includes the tremendous amount of preclinical data that demonstrate numerous positive mechanistic eff ects of EN, including maintenance of gut integrity, attenuated oxidative stress, reduced systemic infl ammation, support of humoral immunity, and enhanced insulin sensitivity, to name a few [3]. However, interestingly Schetz and colleagues argue from a mechanistic point of view that artifi cial nutrition is harmful because it suppresses autophagy. Autophagy undoubtedly has been known since the 1970s to be a critical response to starvation [4]. Activation of autophagy in starvation states is thought to be benefi cial and key for energetic balance. Th is activation occurs via cellular protein breakdown leading to recycling of amino acids in lysosomes, which serves to sustain protein synthesis, even in the absence of amino acids coming from the diet, EN, or PN [4,5]. Th ese amino acids are then available to be utilized directly (although ineffi ciently) to generate ATP via entry at diff erent steps of the Krebs cycle. However, as Schetz and colleagues indicate, this is clearly associated with loss of lean muscle mass. Th is loss of lean body mass significantly contributes to the newly understood epidemic of ICU-acquired weakness [6].
Conversely, absolute gene deletions of key proteins in the autophagy pathway in animal models may also contribute to muscle atrophy [7], although this does not accurately refl ect the patient condition where a balance of autophagy and anabolism are probably needed to optimize outcome. Schetz and colleagues report associations of critical illness with impaired autophagy; however, these are only associations and no focused study causally links impaired autophagy to adverse clinical outcomes. A

Abstract
Recent studies challenge the benefi cial role of artifi cial nutrition provided to critically ill patients and point out the limitations of existing studies in this area. We take a diff ering view of the existing data and refute many of the arguments put forward by previous authors. We review the mechanistic, observational, and experimental data supporting a role for early enteral nutrition in the critically ill patient. We conclude without question that more, high-quality research is needed to better defi ne the role of artifi cial nutrition in the critical care setting, but until then early and adequate delivery of enteral nutrition is a legitimate, evidence-based treatment recommendation and we see no evidence-based role for restricting enteral nutrition in critically ill patients. The role of early supplemental parenteral nutrition continues to be defi ned as new data emerge.

© 2010 BioMed Central Ltd
Does artifi cial nutrition improve outcome of critical illness? An alternative viewpoint! Daren K Heyland* 1 and Paul E Wischmeyer 2

V I E W P O I N T
*Correspondence: dkh2@queensu.ca 1 recent paper by these authors examined the eff ect of signifi cant hyperglycemia on autophagy in an animal model of burn i njury [8]. Th is study found that, not surprisingly, hyperglycemia led to suppressed autophagy (as externally induced, uncontrolled hyperglycemia would clearly suppress autophagy due to nutrient excess). Th ey then found that restoration of normoglycemia improved autophagy, probably by reducing toxic nutrient excess. While quite important descriptive science, the clinical relevance of induced and untreated hyperglycemia in modern clinical ICU practice is limited because hyperglycemia to the levels used in these studies (250 to 350 mg/dl, 13.9 to 19.4 mmol/l) would never be tolerated clinically. Moreover, as the authors acknowledge, the insulin typically used to induce normoglycemia is a potent inhibitor of autophagy [8].
Interestingly, these authors could not confi rm their animal fi ndings in critically ill humans, where no relation ship was observed between improved glucose control and increased autophagy in human postmortem patient biopsies [9]. A balanced autophagy response is therefore probably ideal for optimal outcome. Neither nutrient excess (or overfeeding/hyperglycemia) leading to impaired autophagy nor starvation leading to massive breakdown of lean body mass for ineffi cient energy generation by amino acid stores (or too much autophagy). Th is is probably best achieved by adequate and balanced nutrition application in critical illness, including sufficient protein to minimize cellular and lean body mass losses. Th e ideal dose of each macro nutrient needed to optimize this balance is unknown and is a basic question needing further research.
Finally, a growing body of recent data has shown that the amino acid glutamine is a potent inducer of autophagy [10,11]. Unfortunately, when high doses of glutamine were administered in a pharmacologic fashion very early in severely ill ICU patients with multiorgan failure, mortality was increased [12]! Th us, before any role of autophagy can be used as a justifi cation to feed or not feed in the ICU, a great deal more research is needed to determine whether a real causal role exists for this very important cellular metabolism and immune pathway.
In addition to this mechanistic understanding of the role of nutrition in critical illness and injury, we have large-scale observational studies involving thousands of patients from hundreds of ICUs using statistical techniques adjusting for confounding variables. Th ese large studies consistently describe an association between better nutritional intake and better clinical outcome [13,14]. Yes, there are smaller observational studies that have shown an association in the opposite direction but, as we have shown in a recent paper, limitations to their methodological and statistical approach can easily explain away their fi ndings [14].
We also have 16 randomized trials that test the eff ects of early enteral feeding compared with delayed or no enteral feeding. Since we know that starvation results in death, we fi nd the question of whether to feed illogical and inconsistent with what would be ethically acceptable. More relevant is evaluating the timing of nutritional intervention. Admittedly, there are limitations to these individual trials in terms of their sample size, power, and the nature of the populations studied. However, when meta-analyzed, they suggest an overall treatment eff ect consistent with a large reduction in mortality (relative risk = 0.72, 95% confi dence interval = 0.50 to 1.04, P = 0.08) and infection com pli cations (relative risk = 0.81, 95% confi dence interval = 0.68 to 0.97, P = 0.02) [15].
Finally, we have randomized trials of feeding protocols showing that increased delivery of nutrition is associated with reduced infection, hospital stay, and mortality [16,17]. Taken in their entirety, from the preclinical work to the randomized trials and meta-analysis of randomized trials, we see a consistent signal of benefi t in critically ill patients fed enterally early in the course of illness. We should therefore have confi dence in our clinical recommen da tions to feed early with EN given the homogeneity of the positive signals emanating from these diff erent data sources.
Are the results of randomized trials of intentional underfeeding (hypocaloric or trophic feeds vs. full feeds) suffi cient to refute the hypothesis that early feeding is benefi cial [18,19]? No, because all of the patients in these studies received early EN -what was being tested was the amount of nutrition that patients received. We do not expect artifi cial nutrition, either EN or PN, to benefi t all patients the same. Only patients at high risk nutritionally speaking are likely to derive an eff ect of increased delivery of protein and calories on infection, resolution of organ failure, or mortality [2,20]. It does not matter how large the study is -if low-risk patients (young, undergoing elective surgery, normal to slightly overweight, with short stays) are randomized to diff erent doses of artifi cial nutrition, it will be impossible to detect a treatment eff ect.
Th e EPaNIC trial succeeded in demonstrating a treatment eff ect in low-risk patients only because patients in the early group were harmed by high doses of intravenous glucose administered during the fi rst 2 days of ICU stay [21]. Th ere was an early separation of outcomes in this study (greater proportion of patients remaining mecha nically ventilated >2 days and in the ICU >3 days in the early group vs. the late group) that cannot be attributed to PN since it was not started in the early group until day 3. Th e only diff erence between these two groups during the fi rst 72 hours of randomization was the large glucose load received by the early group. All diff erences observed in this study, and subsequent subgroup and secondary analyses, are probably due to the harm experienced by patients in the early group (even the subgroup of patients with a contraindication of EN). Th is inference is stronger than any inferences made by the authors from post-hoc secondary analysis [22]. Furthermore, this unique and extraordinary practice of glucose loading precludes generali zing these data to any other hospital or ICU worldwide. To support this assertion, we cite two recent large-scale trials that contradict EPaNIC fi ndings and demonstrate the safety of early PN in the ICU setting [23,24].
We conclude by returning to our common ground: we need more high-quality, large-scale randomized trials of nutrition interventions in the ICU setting. Where we disagree is that until the results of such studies are available, let us not throw the baby out with the bath water. Early and adequate delivery of EN is a legitimate, evidence-based treatment recommendation and we see no role for restricting EN in critically ill patients. Th e role of early supplemental PN continues to be defi ned as new data emerge.